We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals

237 hedge funds and large institutions have $6.73B invested in Alnylam Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 106 increasing their positions, 59 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 22

80% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 59

33% more call options, than puts

Call options by funds: $84.9M | Put options by funds: $63.7M

20% more funds holding in top 10

Funds holding in top 10: 1012 (+2)

20% more capital invested

Capital invested by funds: $5.62B → $6.73B (+$1.11B)

10% more funds holding

Funds holding: 215237 (+22)

Holders
237
Holders Change
+22
Holders Change %
+10.23%
% of All Funds
6.32%
Holding in Top 10
12
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+20%
% of All Funds
0.32%
New
47
Increased
106
Reduced
59
Closed
22
Calls
$84.9M
Puts
$63.7M
Net Calls
+$21.2M
Net Calls Change
+$5.1M
Name Holding Trade Value Shares
Change
Change in
Stake
AAM
101
Aureus Asset Management
Massachusetts
$3.65M +$17.2K +170 +0.5%
VOYA Investment Management
102
VOYA Investment Management
Georgia
$3.47M +$256K +2,528 +8%
SEI Investments
103
SEI Investments
Pennsylvania
$3.45M +$3.08M +30,369 +1,150%
BIM
104
BlackRock Investment Management
Delaware
$3.42M +$912K +8,996 +38%
ARTA
105
A.R.T. Advisors
New York
$3.37M +$2.22M +21,946 +212%
TWMP
106
Taylor Wealth Management Partners
Massachusetts
$3.3M +$3.2M +31,601 New
HCM
107
Highbridge Capital Management
New York
$3.17M +$3.08M +30,405 New
CCM
108
Cupps Capital Management
Illinois
$3.1M +$451K +4,454 +18%
PG
109
PEAK6 Group
Illinois
$3.04M +$1.01M +9,958 +52%
DCM
110
Driehaus Capital Management
Illinois
$3.04M -$2.29M -22,640 -44%
PPA
111
Parametric Portfolio Associates
Washington
$2.99M +$432K +4,259 +17%
CS
112
Candriam SCA
Luxembourg
$2.82M -$608K -6,000 -18%
USAA
113
United Services Automobile Association
Texas
$2.82M +$453K +4,470 +20%
Bank of America
114
Bank of America
North Carolina
$2.69M +$1.51M +14,875 +136%
ICM
115
ISZO Capital Management
New York
$2.68M +$2.6M +25,700 New
SFP
116
Santa Fe Partners
New Mexico
$2.68M +$2.6M +25,658 New
PAMU
117
Pictet Asset Management (UK)
United Kingdom
$2.44M +$1.13M +11,148 +87%
UBS Group
118
UBS Group
Switzerland
$2.44M -$1.14M -11,298 -33%
MOACM
119
Mutual of America Capital Management
New York
$2.43M -$67.3K -664 -3%
FAM
120
Fortaleza Asset Management
Illinois
$2.1M -$680K -6,715 -25%
Macquarie Group
121
Macquarie Group
Australia
$2.08M -$625K -6,167 -24%
DIA
122
Denver Investment Advisors
Colorado
$2.07M -$1.79M -17,688 -47%
EEG
123
E.E. Geduld
$1.96M +$836K +8,250 +79%
CAM
124
Chesapeake Asset Management
New York
$1.92M
Public Employees Retirement Association of Colorado
125
Public Employees Retirement Association of Colorado
Colorado
$1.86M +$24K +237 +1%

ALNY Hedge Fund Activity: Q1 2015 in Review

237 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2015, worth a combined $6.73B — up 20% from $5.62B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ALNY positions and 22 closed out — a net gain of 25 holders — while 106 added to existing stakes and 59 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $151M. The largest seller was Franklin Resources, cutting an estimated $103M.

  • 237 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2015, up from 215 in Q4 2014.
  • Funds reported $6.73B of Alnylam Pharmaceuticals stock for Q1 2015, up 20% quarter-over-quarter.
  • 47 funds opened new Alnylam Pharmaceuticals positions in Q1 2015 and 22 closed out, a net change of +25 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q1 2015 was Wellington Management Group, an estimated $151M added.
  • The largest Alnylam Pharmaceuticals seller in Q1 2015 was Franklin Resources, an estimated $103M sold.

Based on aggregated 13F filings for Q1 2015.